| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/23/2009 | US20090186076 Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent |
| 07/23/2009 | US20090186075 Composition |
| 07/23/2009 | US20090186065 Isolating and purifying cells for therapy |
| 07/23/2009 | US20090186052 Use of botulinum toxin for porlonged local desensitization |
| 07/23/2009 | US20090186051 Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
| 07/23/2009 | US20090186050 Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains |
| 07/23/2009 | US20090186049 Method of treating mage positive cancer |
| 07/23/2009 | US20090186048 Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| 07/23/2009 | US20090186047 HCV Vaccinations |
| 07/23/2009 | US20090186046 Hepatitis C Virus Non Structural Fusion Protein |
| 07/23/2009 | US20090186045 Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| 07/23/2009 | US20090186044 Type iv collagen-like immunoreactive peptide |
| 07/23/2009 | US20090186043 Method and compositions for preventing and treating streptococcus pneumoniae infection |
| 07/23/2009 | US20090186042 Identification and use of novopeptides for the treatment of cancer |
| 07/23/2009 | US20090186041 Anti-tsg101 antibodies and their uses for treatment of viral infections |
| 07/23/2009 | US20090186040 DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT |
| 07/23/2009 | US20090186039 Novel use of grp 94 in virus infection |
| 07/23/2009 | US20090186038 Methods of Preventing or Treating Respiratory Conditions |
| 07/23/2009 | US20090186037 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 07/23/2009 | US20090186036 Anti-Alpha V Beta 6 Antibodies |
| 07/23/2009 | US20090186035 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 07/23/2009 | US20090186034 Gene expression markers for inflammatory bowel disease |
| 07/23/2009 | US20090186033 Anti-amyloid immunogenic compositions, methods and uses |
| 07/23/2009 | US20090186032 Bio-Markers For Diagnosing Diabetic Retinopathy |
| 07/23/2009 | US20090186031 Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins |
| 07/23/2009 | US20090186030 Antibodies that bind both bcma and taci |
| 07/23/2009 | US20090186029 Anticholesterol agents; generating an antibody which binds specifically to a C-terminal fragment of a vertebrate hedgehog polypeptide, comprising immunizing a mammalian subject with the C-terminal fragment |
| 07/23/2009 | US20090186028 Detection of mutations in a gene associated with resistance to viral infection |
| 07/23/2009 | US20090186027 Single chain antibodies against beta-amyloid peptide |
| 07/23/2009 | US20090186026 Ephrin and eph receptor agonists for modulation of bone formation and resorption |
| 07/23/2009 | US20090186025 Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating an Immune Response |
| 07/23/2009 | US20090186024 Gene Expression Signatures for Oncogenic Pathway Deregulation |
| 07/23/2009 | US20090186023 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions |
| 07/23/2009 | US20090186022 Organic Compounds |
| 07/23/2009 | US20090186021 Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| 07/23/2009 | US20090186020 Melanocortin Receptor Binding Mimetibodies, Compositions, Methods and Uses |
| 07/23/2009 | US20090186019 Inducing lysis of tumor cells that expresses epidermal growth factor receptor; antiproliferative agents |
| 07/23/2009 | US20090186018 Compositions and methods for the treatment of rheumatoid arthritis |
| 07/23/2009 | US20090186017 Graft-Versus-Host Disease Predicting Marker and Use Thereof |
| 07/23/2009 | US20090186016 Augmentation of endothelial thromboresistance |
| 07/23/2009 | US20090186015 Micrornas differentially expressed in lung diseases and uses thereof |
| 07/23/2009 | US20090186014 Method for treatment of pancreatitis |
| 07/23/2009 | US20090186008 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| 07/23/2009 | US20090185997 Methods of suppressing microglial activation and systemic inflammatory responses |
| 07/23/2009 | US20090185979 Integrin Heterodimer and an Alpha Subunit Thereof |
| 07/23/2009 | US20090185978 Monoclonal antibody capable of binding integrin alpha 10 beta 1 |
| 07/23/2009 | US20090185974 Chimeric, Human and Humanized Anti-Granulocyte Antibodies and Methods of Use |
| 07/23/2009 | CA2712475A1 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant |
| 07/23/2009 | CA2712404A1 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| 07/23/2009 | CA2712298A1 Improved anti-trkb antibodies |
| 07/23/2009 | CA2711984A1 Powdered protein compositions and methods of making same |
| 07/23/2009 | CA2711938A1 Methods for manipulating phagocytosis mediated by cd47 |
| 07/23/2009 | CA2711930A1 A truncated form of the hiv p17 protein |
| 07/23/2009 | CA2711902A1 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart |
| 07/23/2009 | CA2711763A1 Methods of treating bone-loss disorders using a gm-csf antagonist |
| 07/23/2009 | CA2711736A1 Cysteine engineered antibodies for site-specific conjugation |
| 07/23/2009 | CA2711145A1 Immunomodulating compositions and uses therefor |
| 07/23/2009 | CA2710912A1 Afucosylated antibodies against ccr5 and their use |
| 07/23/2009 | CA2710814A1 Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation |
| 07/23/2009 | CA2710619A1 Inhibiting angiogenesis using egfl8 antagonists |
| 07/23/2009 | CA2710186A1 Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins |
| 07/22/2009 | EP2080804A1 Modified cytokines for use in cancer therapy |
| 07/22/2009 | EP2080802A2 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 07/22/2009 | EP2080772A2 Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against TSH receptor |
| 07/22/2009 | EP2080525A1 Remodeling and Glycoconjugation of Peptides |
| 07/22/2009 | EP2080522A1 Thermoreversible immuno-adjuvant emulsion |
| 07/22/2009 | EP2080521A1 Gastrin compositions and formulations, and methods of use and preparation |
| 07/22/2009 | EP2079760A2 Compositions and methods for the treatment of infections and tumors |
| 07/22/2009 | EP2079484A2 Monitoring cancer stem cells |
| 07/22/2009 | EP2079483A2 Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug |
| 07/22/2009 | EP2079481A1 Vaccine peptide combinations against cat allergy |
| 07/22/2009 | EP2006377A9 Novel tumor antigen peptides |
| 07/22/2009 | EP1940464B1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 07/22/2009 | EP1863846B1 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| 07/22/2009 | EP1804822B1 Hcv vaccines for chronic hcv patients |
| 07/22/2009 | EP1713830B1 Anti-epcam immunoglobulins |
| 07/22/2009 | EP1706424B1 Fc region variants |
| 07/22/2009 | EP1597359B1 Inactivated nodavirus vaccine |
| 07/22/2009 | EP1597274B1 Hsp60 from arthrobacter |
| 07/22/2009 | EP1506008B1 Mucosal vaccines with chitosan adjuvant and/or meningococcal antigens |
| 07/22/2009 | EP1471937B1 A continuous cell line for the production of vaccines |
| 07/22/2009 | EP1357938B1 Hyperblebbing bacterial strains and use thereof for production of vaccines |
| 07/22/2009 | EP1297110B1 Attenuated bovine respiratory syncytial virus |
| 07/22/2009 | EP1280900B1 Dendritic cell co-stimulatory molecules |
| 07/22/2009 | EP1255563B1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/22/2009 | EP1235853B1 Multimeric forms of tnf superfamily ligands |
| 07/22/2009 | EP1231840B1 Anti-angiogenic cellular agent for cancer therapy |
| 07/22/2009 | EP1220922B1 Method of identifying a compound with efficacy in the treatment of chronic inflammatory diseases |
| 07/22/2009 | EP1131461B1 Use of hydroxamate compounds for the treatment of HER-2/neu-positive carcinomas |
| 07/22/2009 | EP1093381B2 Antigenic peptides derived from telomerase |
| 07/22/2009 | EP1044018B1 Tumour vaccines for muc1-positive carcinomas |
| 07/22/2009 | EP0873135B1 Peanut allergens and methods |
| 07/22/2009 | CN101489589A Immunogenic compositions |
| 07/22/2009 | CN101489588A Bioactive purified HspE7 compositions |
| 07/22/2009 | CN101489587A A composition useful as a vaccine |
| 07/22/2009 | CN101489586A Influenza vaccine |
| 07/22/2009 | CN101489585A Method of immunisation against the four serotypes of dengue |
| 07/22/2009 | CN101489584A Recombinant attenuated clostridium organisms and vaccine |
| 07/22/2009 | CN101486766A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 07/22/2009 | CN101486756A Outer surface proteins, their genes, and their use |